Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

Financials ($)
Sales 2016 16 714 M
EBIT 2016 7 822 M
Net income 2016 -193 M
Debt 2016 13 925 M
Yield 2016 -
Sales 2017 18 231 M
EBIT 2017 8 914 M
Net income 2017 2 879 M
Debt 2017 9 161 M
Yield 2017 -
P/E ratio 2016 648,59
P/E ratio 2017 98,68
EV / Sales2016 6,82x
EV / Sales2017 5,99x
Capitalization 100 056 M
More Financials
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.The firm offers products under the following brands: BOTOX, Juvederm, Linzess, Namenda, Restasis, Latisse, Teflaro, Lo Loestrin Fe, Bystolic, DORYX, Saphris, Fetzima, Namenda XR, Namzaric, Viberzi,... 
08/08 | 01:30pmEarnings Release
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACTAVIS INC
07/28DJFacebook Rides Mobile-Ad Surge -- WSJ
07/27 Teva, Allergan win U.S. antitrust approval for generics deal
07/27DJTEVA PHARMACEUTICAL : Correction to Teva, Allergan Article
07/27DJTEVA PHARMACEUTICAL : Allergan Get FTC Approval for Generics Purchase
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/20DJJOHNSON & JOHNSON : Jury Acquits Former Johnson & Johnson Unit Executives of Fel..
07/20DJJOHNSON & JOHNSON : Jury Acquits Former Johnson & Johnson Unit Executives of Fel..
07/19 SoftBank bid for ARM catches some hedge funds off guard
07/18DJTEVA PHARMACEUTICAL : Sells $15 Billion of Bonds
07/18DJTEVA PHARMACEUTICAL : Finalizes Bond Sale -- Update
More news
Sector news : Pharmaceuticals - NEC
08:48aDJMERCK : Earnings Watch -- WSJ
01:14a BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 289 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Brenton L. Saunders President, Chief Executive Officer & Director
Paul M. Bisaro Executive Chairman
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-9.99%218 231
NOVARTIS AG-5.30%215 109
MERCK & CO., INC.11.06%162 372
More Results